281 related articles for article (PubMed ID: 12386641)
1. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
3. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
4. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
6. Drotrecogin alfa (activated).
Lyseng-Williamson KA; Perry CM
Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
[TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
8. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
9. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
[TBL] [Abstract][Full Text] [Related]
11. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis.
Olsen KM; Martin SJ
Pharmacotherapy; 2002 Dec; 22(12 Pt 2):196S-205S. PubMed ID: 12492226
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
16. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
Rudis MI; Fish DN
Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
[TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
[TBL] [Abstract][Full Text] [Related]
19. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
Laterre PF; Wittebole X
Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
[TBL] [Abstract][Full Text] [Related]
20. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
